Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Gilead sciences, inc. save search
Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients
Published: 2022-08-30 (Crawled : 13:00) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -20.58%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.1%
H: 0.29%
C: -0.02%
trial therapeutics results phase 2
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Published: 2021-11-11 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
phase 2 china cancer phase 2b breast cancer
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
Published: 2021-10-26 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
treatment phase 2 hiv
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
Published: 2021-06-07 (Crawled : 23:00) - globenewswire.com
HOOK | $0.7317 -4.34% -4.54% 420K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: -20.15%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.03%
H: 0.25%
C: 0.1%
phase 1 therapy cancer phase 3 phase 2 t-cell
HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO
Published: 2021-05-20 (Crawled : 12:15) - biospace.com/
HOOK | $0.7317 -4.34% -4.54% 420K
|
Health Technology
|
| O: -2.84%
H: 0.54%
C: -9.78%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.23%
H: 1.92%
C: 1.0%
treatment phase 1 cancer phase 3 phase 2
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Published: 2021-04-28 (Crawled : 12:15) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -0.3%
H: 0.3%
C: -3.8%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.03%
H: 0.02%
C: -0.39%
phase 2 clinical trials phase 1 trial phase 3
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
Published: 2021-03-31 (Crawled : 03:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -1.09%
phase 2 china cancer trial approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.